FDA approves new type of nonopioid painkiller for acute pain
The drug, Journavx, from Vertex Pharmaceuticals, reduced pain after surgery in clinical trials. Experts hope it can lead to fewer opioid prescriptions.
Seeking Alpha3h
2025 Will Be A Major Year For ProKidney's Rilparencel In CKD Treatment
Currently, Rilparencel’s Phase 3 is planned to deliver full data by Q3 2027 if no surrogate endpoint is found that’s suitable ...
Frontiers4h
Modifiable Risk Factors for Chronic Kidney Disease Progression
Chronic kidney disease (CKD) is a growing global health concern, significantly contributing to morbidity and mortality rates worldwide. Characterized by a ...
Q&A: How a scientist helped ban a chemical connected to Parkinson's disease
The U.S. will ban nearly all uses of the common industrial cleaning agent, trichloroethylene (TCE), this year—more than 50 ...
FDA approves Ozempic to help reduce risk of worsening chronic kidney disease
The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...
verywellhealth18h
Doctors Can Now Prescribe Ozempic to Reduce Kidney Disease Risks in Diabetes Patients
The FDA has approved popular antiobesity drug Ozempic to help protect patients with type 2 diabetes from kidney disease.
New FDA Approval: Ozempic Gets Nod For Kidney Protection In Type 2 Diabetes
The FDA has approved Ozempic to reduce kidney failure risk in people with type 2 diabetes and chronic kidney disease. Studies ...
Renal & Urology News23h
KDIGO Issues New ADPKD Guideline
KDIGO guideline is the first specifically addressing autosomal dominant polycystic kidney disease (ADPKD) and focuses on some unique aspects of management.